Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Taking the Stage: Scientific Conferences

Our scientists and clinicians are global experts in their field. The University of Kansas Cancer Center faculty present their work at dozens of scientific conferences each year.

Media inquiry? The cancer center communications team works with media to facilitate information requests and connect them with experts. Learn more.

Recent and Past Conferences

Abstracts listed below involve KU cancer center members and consortium partners Stowers Institute for Medical Research and Children’s Mercy.

  • Case-Based Panel Session: Understanding and Managing Chronic Effects of the Cancer Experience.
    Available via pre-broadcast on June 4, 2021
    Panel chair: Sean Robinson Smith
    Panelists: Judith Paice, Candace Henley, Jamie S. Myers.

    Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Abstract 7033: Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.
    Muhammad Umair Mushtaq, Mary Luder, Moazzam Shahzad, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Sibgha Gull Chaudhary, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K Singh, Sunil H. AbhyankarSiddhartha GangulyJoseph McGuirk.

    Session: Prevention, Risk Reduction, and Hereditary Cancer
    Abstract 10580:  Point of care genetic testing in a breast cancer survivorship clinic.
    Lori Ranallo, Lauren Elizabeth Nye, Mary Williams, Carol J. FabianAnne O'DeaJennifer R. Klemp.

    Abstract 10502:  Ancestrally unbiased polygenic breast cancer (BC) risk assessment.
    Elisha Hughes, Placede Tiemeny, Shannon Gallagher, Stephanie Meek, Charis Eng, Monique Gary, Ora Gordon, Jennifer R. Klemp, Olufunmilayo I. Olopade, Holly Jane Pederson, Jeffrey N. Weitzel, Pat W. Whitworth, Lamis Yehia, Susanne Wagner, Thomas Paul Slavin, Alexander Gutin, Jerry Lanchbury

    Session: Health Services Research and Quality Improvement
    Abstract 6552:  Effect of income on patient decision-making in localized prostate cancer.
    Xinglei Shen, Ying Cao, Aaron J. Katz, Deborah Usinger, Sarah Walden, Ronald C. Chen

    Abstract 6578:  Associations between patient knowledge of others' experiences and treatment choice in men with localized prostate cancer.
    Aaron J. Katz, Ying Cao, Xinglei Shen, Deborah Usinger, Sarah Walden, Ronald C. Chen

    Abstract 6556:  In-hospital outcomes of CAR T-cell therapy in United States in 2018: A nationwide analysis.
    Manoj P. Rai, Prabhjot Singh Bedi, Anup KasiKathan Mehta

    Abstract 6519:  Racial and ethnic representation trends in United States oncology training programs.
    Conner Lombardi, Jacob Lang, Rochell Issa, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

    Abstract 6509:  Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.
    Kathryn Finch Mileham, Suanna Steeby Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel Mesenhowski, Alexander I. Spira, Eric J. Clayton, David Michael Waterhouse, Sue Moore, Abdul-Rahman Jazieh, Ronald C. Chen, Melinda Kaltenbaugh, Jen Hanley Williams, Richard L. Schilsky, Liz Garrett-Mayer

    Abstract 6500:  Racial and ethnic disparities among patients with breast cancer and COVID-19.
    Gayathri Nagaraj, Melissa Kate Accordino, Benjamin French, Nicole M. Kuderer, Gary H. Lyman, Daniel G. Stover, Victoria Susana Blinder, Andrew Lachlan Schmidt, Rebecca Arielle Shatsky, Punita Grover, Matthew Puc, Clara Hwang, Elizabeth Marie Wulff-Burchfield, Mark Andrew Lewis, Alvaro G. Menendez, Mehmet Asim Bilen, Jeremy Lyle Warner, Maryam B. Lustberg, Dimpy P Shah

    Session: Developmental Therapeutics—Immunotherapy
    Abstract TPS2678:  Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.
    Takefumi Komiya, Jun ZhangPrakash C. NeupaneKathan MehtaChao Hui Huang

    Abstract 2510:  Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
    Stephen K. Williamson, F. Stephen Hodi, Melissa Lynne Johnson, Minal A. Barve, Dejan Juric, Joaquina Celebre Baranda, Reva Elaine Schneider, Todd Michael Bauer, Tun Tun Lin, Rui Wang, Amele Amrate, Helene Guillemin-Paveau, Ryan J. Sullivan

    Abstract 2534:  PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.
    Matthew H. Carabasi, Meredith McKean, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Russell Kent Pachynski, Rahul Atul Parikh, Jingsong Zhang, Thomas J. Fountaine, Jamie Rosen, Pam Hufner, Whitney Gladney, Karen Chagin

    Abstract 2536:  Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.
    Antonio Jimeno, Joaquina Celebre Baranda, Monica M. Mita, Michael S. Gordon, Matthew H. Taylor, Wade Thomas Iams, Filip Janku, Ursula A. Matulonis, Howard Bernstein, Scott Loughhead, Martin Kornacker, Ricardo F. Zwirtes, Oliver Rosen, Cathy Eng

    Abstract TPS2661: Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
    Adam Jacob Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra P. D'Angelo, Brian H. Ladle, Jonathan Christopher Noujaim, Kai He, David A. Liebner, Adrian G. Sacher, John B. A. G. Haanen, Jeffrey Yachnin,Chao H. Huang, Brian Andrew Van Tine, Aisha N. Hasan, Thomas H. Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo

    Session: Breast Cancer—Metastatic
    Abstract 1076:  Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).
    Priyanka Sharma, Vandana G Abramson, Anne O'DeaLauren Elizabeth Nye, Ingrid A. Mayer, Gregory James Crane, Manana Elia, Rachel Yoder, Joshua M Staley, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Stephen K. Williamson, Milind Phadnis, Gregory A Reed, Bruce F. KimlerQamar J. KhanAndrew K. Godwin

    Abstract 1077:  Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Joyce O'Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Hope S. Rugo

    Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Abstract TPS7058:  A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.
    Abdulraheem Yacoub, Susan Erickson-Viitanen, Feng Zhou, Albert Assad

    Abstract 7026:  Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
    Vinod Pullarkat, Mark J. Levis, Gabriel N. Mannis, Stephen Anthony Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald Cheung, Harry Paul Erba

    Session: Gastrointestinal Cancer—Colorectal and Anal
    Abstract 3357:  Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.
    Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed

    Abstract 3563:  Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
    Emil Lou, Yasmine Baca, Joanne Xiu, Andrew Nelson, Subbaya Subramanian, Mohamed E. Salem, Muhammad Shaalan Beg, Elisa Fontana, Maria Diab, Philip Agop Philip, Richard M. Goldberg, Ritu Pandey, Tobias Arkenau, Weijing Sun, Heinz-Josef Lenz, Anthony Frank Shields, Wafik S. El-Deiry, Wolfgang Michael Korn

    Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
    Abstract 4091:  Relationship between Helicobacter pylori and development of hepatocellular carcinoma: A systematic review and meta-analysis.
    Samragnyi Madala, Kira MacDougall, Balarama Krishna Surapaneni, Robin Park, Anup Kasi, Mohit Girotra

    Abstract 4086:  Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
    Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh'd Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David H. Gallinson, Adrian Gerard Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Christine Francis Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel

    Abstract 4085: Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.
    Alessio Cortellini, Thomas Urban Marron, Pallavi Shruti Mishra-Kalyani, Yutao Gong, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Uqba Khan, Ahmed Omar Kaseb, Yi-Hsiang Huang, Celina Ang, Julie A. Schneider, Anjana Pillai, Lorenza Rimassa, Richard Pazdur, Marc Robert Theoret, Steven Lemery, Lorraine Cheryl Pelosof, David James Pinato

    Session: Sarcoma
    Abstract TPS11578:  A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
    Jay Oza, Shing Mirn Lee, Mia C. Weiss, Brittany L Siontis, Benjamin C. Powers, Warren Allen Chow, Wendy Magana, Tahir Sheikh, Richard Piekarz, Gary K. Schwartz, Matthew Ingham

    Abstract 11523:  Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
    Michael J Wagner, Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah, Ali Raza Khaki, Lisa May Ling Tachiki, Elizabeth Trice Loggers, Chris Labaki, Rana R. McKay, Elizabeth A. Griffiths, Katherine Anne Thornton, Anup Kasi, Clara Hwang, James Lin Chen, Thorvardur Ragnar Halfdanarson, Daniel Y. Reuben, Cathleen Park, Elizabeth J. Davis

    Session: Professional Development and Education Advances
    Abstract 11020:  Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.
    Raheel Sufian Siddiqui, Moazzam Shahzad, Mahrukh Majeed, Ali Hussain, Faryal Murtaza, Farhan Khalid, Ayesha Habib, Zobia Aijaz, Syeda Sadia Bukhari, Iqra Anwar, Sehar Altaf, Faiz Anwer, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Siddhartha Ganguly, Sunil H. Abhyankar, Joseph McGuirk, Faisal Khosa, Muhammad Umair Mushtaq

    Abstract 11043:  Representation trends in radiation oncology training programs in the United States.
    Emilie Garcia, Jacob Lang, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

    Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
    Abstract TPS7570:  A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
    Joseph McGuirk, Carlos R. Bachier, Michael Russell Bishop, P. Joy Ho, Hemant S. Murthy, Michael J. Dickinson, Joseph E. Maakaron, Charalambos Andreadis, Armin Ghobadi, Edmund K. Waller, Mark Daniel Benton, Susanna Suh, Huansheng Xu, Ewelina Morawa, Farrukh Tauseef Awan, Paul Shaughnessy, Constantine Si Lun Tam, Nicolaus Kroeger, Richard T. Maziarz

    Session: Genitourinary Cancer—Kidney and Bladder
    Abstract 4568:  Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.
    Dharmesh Gopalakrishnan, Katharine Collier, Joseph J Park, Jacob P Zaemes, Elaine Tat Lam, Sabah Alaklabi, Ellen Jaeger, Rahul Atul Parikh, Pedro C. Barata, Eric Kauffman, Michael B. Atkins, Ajjai Shivaram Alva, Yuanquan Yang, Saby George

    Abstract 4507:  A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
    Authors:  Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, Rahul Atul Parikh, Benjamin A. Teply, Robert Dreicer, Hamid Emamekhoo, M. Dror Michaelson, Christopher J. Hoimes, Tian Zhang, Sandy Srinivas, William Y. Kim, Glenn Liu, Paul Henry Frankel, Yuijie Cui, Primo "Lucky" N. Lara

    Abstract TPS4593:  A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
    Authors:  Rana R. McKay, Heather Jacene, Pamela J. Atherton, Gabriela Perez Burbano, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler J. Zemla, Ronald C. Chen, Atish Dipankar Choudhury, Joshua Michael Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Himisha Beltran, Daniel J. George, Michael J. Morris, Toni K. Choueiri

    Session: Gynecologic Cancer
    Abstract 5576:  Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Filip Janku, Erika P. Hamilton, Cara Amanda Mathews, Christina Chu, Jennifer Robinson Diamond, John L. Hays, Rebecca Christian Arend, Massimo Cristofanilli, Andrea Jewell, William Reichmann, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, Debra L. Richardson

    Session: Genitourinary Cancer—Prostate, Testicular, and Penile
    Abstract 5071:  The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
    Andrew J. Armstrong, Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Zelig Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgioti, Nader N. El-Chaar, Arnulf Stenzl
      
    Session: Symptoms and Survivorship
    Abstract 12035:  Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.
    Elizabeth Trice Loggers,Elizabeth Marie Wulff-Burchfield, Ishwaria Mohan Subbiah, Ali Raza Khaki, Pamela Egan, Dimitrios Farmakiotis, Hardeep Phull, Elizabeth Nakasone, Chris Labaki, Peter Paul Yu, Monika Joshi, Elizabeth A. Griffiths, Trisha Michel Wise-Draper, Chinmay Jani, Astha Thakkar, Matthew Puc, Clara Hwang, Blanche H. Mavromatis, Dimpy P Shah, Jeremy Lyle Warner

    Session: Melanoma/Skin Cancers
    Abstract 9515:  Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
    Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa Lynne Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, Alexander I. Spira, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha Nicholle Sims, Glenn Kroog

    Session: Biomarker-Driven Approaches for the Treatment of Gastrointestinal Cancers
    Abstract 4010:  FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
    Daniel V.T. Catenacci, Yoon-Koo Kang, Anwaar Saeed, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee, In-Ho Kim, Sang Cheul Oh, Jin Li, Haci M. Turk, Alexandra Carolina Teixeira, Christophe Borg, Erika Hitre, Anghel Adrian Udrea, Giovanni Gerardo Cardellino, Raquel Guardeno, Siddhartha Mitra, Yingsi Yang, Peter C. Enzinger, Zev A. Wainberg

    Session: Pediatric Oncology
    Abstract 10051:  Standardization of fertility preservation discussion amongst pediatric oncology and bone marrow transplant patients.
    Chandni Dargan, Sarah Mc Dermott, Shelby Chesbro, Joy M. Fulbright

    Session: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
    Abstract e16194:  Efficacy of immunotherapy in hepatocholangiocarcinoma (HCC-CC): Proof of concept.
    Osama Diab, Maloree Khan, Saqib Abbasi, Anwaar Saeed, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Raed Moh'd Taiseer Al-Rajabi

    Abstract e16273:  Early detection of pancreatic cancers by novel nanobiosensor-based protease biomarkers using hierarchical decision structure.
    Anup Kasi, Weijing Sun, Sumia Ehsan, Jose Covarrubias, Kayla Eschliman, Raul Neri, Deepesh Agarwal, Obdulia Covarrubias Zambrano, Stefan H Bossmann, Bala Natarajan

    Session: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
    Abstract e15613:  A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
    Anup Kasi, Pramod Gaudel, Joseph Bennett, Raed Moh'd Taiseer Al-RajabiAnwaar Saeed, Joaquina Celebre Baranda, Weijing Sun, Charles B. Porter

    Session: Publication Only: Health Services Research and Quality Improvement
    Abstract e18578:  Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.
    Robin Park, Elizabeth Marie Wulff-Burchfield,Kathan Mehta,Weijing Sun,Anup Kasi

    Abstract e18562:  Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART.
    Nausheen Ahmed, Ernie Shippey, Crissy Kus, Allison Appenfeller, Marc Steven Hoffmann, Aung M. Tun, Siddhartha Ganguly,Leyla Shune, Clint Devine, Rajat Bansal, Sunil H. Abhyankar, Muhammad Umair Mushtaq, Joseph McGuirk

    Abstract e18611:  Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.
    Sibgha Gull Chaudhary, Muhammad Usman Zafar, Maha Awaiz Hassan, Moazzam Shahzad, Ali Hussain, Fatima Ali, Yumna Riaz, Fatima Khalid, Sharad Khurana, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh, Faiz Anwer, Sunil H. Abhyankar,Joseph McGuirk, Muhammad Umair Mushtaq

    Session: Publication Only: Care Delivery and Regulatory Policy
    Abstract e13615:  Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.
    Nausheen Ahmed, Sarah Fitzmaurice, Cherie Morey, Tania Torres, Darla Beckman, Siddhartha Ganguly, Rajat Bansal, Liza Rodriguez, Haitham Abdelhakim, Anurag K Singh,Sunil H. Abhyankar, Leyla Shune, Robert Kribs, Clint Devine, Jennifer Hanses, Muhammad Umair MushtaqJoseph McGuirk

    Session: Publication Only: Lung Cancer—Non-Small Cell Metastatic
    Abstract e21024:  Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
    Justin Chau, Meeta Yadav, Ben Liu, Muhammad Furqan, Qun Dai, Shailesh Shahi, Arnav Gupta, Keri Nace Mercer, Evan Eastman, Taher Abu Hejleh, Carlos Hou Fai Chan, George J. Weiner, Catherine Cherwin, Sonny T.M. Lee, Cuncong Zhong, Ashutosh Mangalam, Jun Zhang
      
    Session: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
    Abstract e17012:  Nationwide trends in in-patient chemotherapy hospitalizations, cost, and mortality for patients with testicular carcinoma.
    Saqib Abbasi, Elizabeth Marie Wulff-Burchfield,Rahul Atul Parikh

    Abstract e17020:  A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.
    Rana R. McKay, Wanling Xie, Archana Ajmera, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Atish Dipankar Choudhury, David Johnson Einstein, Elisabeth I. Heath, Rahul Atul Parikh, Charles Kunos, S. Percy Ivy, Geoffrey Shapiro, Razelle Kurzrock

    Session: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
    Abstract e19537:  Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
    Ulrich Jäger, Nina Worel, Joseph McGuirk, Peter A. Riedell, Isabelle Fleury, Peter Borchmann, Yan Du, Ahmed M. Abdelhady, Xia Han, Marcela Martinez-Prieto, Edmund K. Waller

    Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Abstract e19014:  Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.
    Syed Ather Hussain, Atif N khan, VENKATA S THAMMINENI, Muhammad Nauman Riaz, Moazzam Shahzad, Priyanjali Pulipati, Fatima Khalid, Zahoor Ahmed, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Muhammad Umair Mushtaq

    Abstract e19002:  MRD assessment using NGS in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation: Meta-analysis.
    Osama Mosalem, Mahmoud Abdelsamia, Haitham Abdelhakim

    Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Abstract e19035:  Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.
    Razwana Khanam, Moazzam Shahzad, Pranali Santhoshini Pachika, Zahoor Ahmed, Fatima Ali, Adeel Masood, Zunairah Shah, Asmi Chattaraj, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Sunil H. Abhyankar,Joseph P McGuirk, Muhammad Umair Mushtaq

    Abstract e19025: Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.
    Abdul Basit, Moazzam Shahzad, Sibgha Gull Chaudhary, Fatima Khalid, Nausheen Ahmed, Sharad Khurana, Siddhartha Ganguly,Sunil H. AbhyankarJoseph McGuirk, Muhammad Umair Mushtaq

    Abstract e19012: Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.
    Moazzam Shahzad, Iqra Anwar, Raheel Sufian Siddiqui, Tehniat Faraz Ahmed, Mahrukh Majeed, Maha Awaiz Hassan, Zahoor Ahmed, Karun Neupane, Tayyaba Ali, Muhammad Salman Faisal, Masooma Naseem, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh,Sunil H. Abhyankar,Joseph McGuirk, Faiz Anwer, Muhammad Umair Mushtaq

  • April 9
    SY02.OD - Options and Opportunities for Treating Metastasis

    On Demand
    Friday, April 9, 2021: 12:05 AM - 11:59 PM

    Chairperson: Danny R. Welch (CB)
    Using the hallmarks of metastasis to develop antimetastatic treatments

    April 10
    PO.CL06.03 - Immune Checkpoints
    485 - Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study.

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Petros Fessas, Muntaha Naeem, Thomas U. Marron, David Szafron, Elad Sharon, Anwaar Saeed (D3ET), Tomi Jun, Sirish Dharmapuri, Abdul R. Naqash, Thoetchai Peeraphatdit, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, ChiehJu Lee, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, David J. Pinato.

    PO.CL06.04 - Immune Mechanisms Invoked by Therapies
    505 - Oral azacitidine modulates the immune microenvironment in acute myeloid leukemia (AML) patients in remission: A subanalysis from the QUAZAR AML-001 Trial

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Daniel L. Menezes, Wendy L. See, Alberto Risueno, Jianglin Ma, Ignazia La Torre, Barry Skikne, CL Beach, Keshava Kumar, Anjan Thakurta.

    PO.CL06.05 - Immune Monitoring / Clinical Correlates
    509 - Conversion of cellular kinetic data for chimeric antigen receptor T-cell therapy (CAR-T) into interpretable units

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Anwesha Chaudhury, Andrew Stein, Stephan Grupp, John Levine, Michael Pulsipher, G Doug Myers (D3ET), Edward Waldron, Xu Zhu, Fraser McBlane, Rakesh Awasthi, Edmund K. Waller. 

    510 - Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL)
    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Irina Gershgorin, Edward R. Waldron, Stephan A. Grupp, John E. Levine, Michael A. Pulsipher, Stella M. Davies, G. Doug Myers (D3ET), Margit Jeschke, Boris Engels, Chris Del Corral, Andre Baruchel. 

    PO.CT01 - Phase I Clinical Trials
    CT131 - A Phase I safety and tolerance study of FN-1501, a novel FLT3 inhibitor, in patients with advanced solid tumors and acute myeloid leukemia

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Gary Edward Richardson, Stephen K. Williamson (D3ET), Misako Nagasaka, Viviana Bozon, Maria Margarita Corvez, Chao Li, Wei Li, Jiao Wei, Ai-Min Hui.

    PO.CT02 - Phase II Clinical Trials
    CT162 - Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Abdulraheem Yacoub (D3ET), Eunice S. Wang, Raajit K. Rampal, Uma Borate, Marina Kremyanskaya, Haris Ali, Gabriela S. Hobbs, Casey O'Connell, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Timothy C. Burn, Naval G. Daver.

    CT164 - Pharmacological ascorbate enhances platinum-based chemotherapy responses in metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial
    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Muhammad Furqan, Taher Abu-Hejleh, Kellie L. Bodeker, Laura M. S. Pietrok, Stacey M. Hartwig, Mikaela M. Tremblay, Micaela G. Fosdick, Jon Houtman, Steven Varga, Casey F. Pulliam, Michael Petronek, Melissa A. Fath, Sarah L. Mott, Aaron D. Bossler, Andrew M. Bellizzi, Jun Zhang (D3ET), Hariharasudan Mani, Varun Monga, Brian J. Smith, Joseph Cullen, Brett A. Wagner, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen.

    PO.CT08.01 - Phase I Clinical Trials in Progress
    CT219 - Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Adam J. Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra D’Angelo, Brian H. Ladle, Jonathan Noujaim, Kai He, David Liebner, Adrian G. Sacher, John B.A.G. Haanen, Jeffrey Yachnin, Chao Huang (D3ET), Brian A. Van Tine, Aisha Hasan, Thomas Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo.

    PO.CT08.03 - Phase III Clinical Trials in Progress
    CT252 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Abdulraheem Yacoub (D3ET), Sue Erickson-Viitanen, Feng Zhou, Albert Assad.

    CT253 - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Abdulraheem Yacoub (D3ET), Michael Stouffs, Feng Zhou, Albert Assad.

    PO.EP01.02 - Biomarkers of Prognosis
    774 - Methylation-derived biologic age, telomere length, and lung cancer mortality in heavy smokers from CARET

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Laurie Grieshober, Stefan Graw, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Chu Chen, Devin C. Koestler (CB), Carmen J. Marsit, Jennifer A. Doherty.

    PO.EP01.11 - Infection and Immune Factors
    LB086 - Methylation-derived neutrophil-to-lymphocyte ratio and lung cancer risk and survival

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Naisi Zhao, Mengyuan Ruan, Devin C. Koestler (CB), Jiayun Lu, Carmen Marsit, Karl Kelsey, Elizabeth Platz, Dominique S. Michaud.

    PO.ET03.05 - Reversal of Drug Resistance
    1413 - Targeting the RNA-binding protein HuR to overcome chemoresistance in triple-negative breast cancer

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Lanjing Wei, Qi Zhang, Cuncong Zhong, Jeffrey Aubé, Danny R. Welch (CB)Xiaoqing Wu (D3ET)Liang Xu (D3ET).

    PO.IM02.02 - Combination Immunotherapies
    1560 - Targeting RNA-binding protein HuR to improve anti-PD-1 immunotherapy response in breast cancer

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Qi Zhang, Xiaoqing Wu (D3ET), Lan Lan, Lanjing Wei, Liang Xu (D3ET).

    PO.MCB08.04     
    2467 - Adiponectin receptor agonism induces a metabolic switch in pancreatic cancer cells from oxidative phosphorylation to glycolysis

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Sharon J. Manley, Jarrid Jack, Joseph Ambrose, Appolinaire A. Olou, Michael N. VanSaun (CB)

    PO.PR01.01 - Preclinical Prevention, Early Detection, and Interception
    2567 - Duavee® improves metabolic health without increasing cancer risk: findings from a preclinical model of obesity and postmenopausal breast cancer

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Karen A. Corleto, Tara N. Mahmood, Danilo Landrock, Stephen D. Hursting, Carol J. Fabian (CPC), Bruce F. Kimler (CPC), Erin D. Giles.

    PO.TB04.02 - Invasion and Metastasis 2
    2899 - On the cutting edge of the leading edge: investigating the role of DCLK1 in invadopodia

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Levi K. Arnold, Michael Barry, Prabhu Ramamoorthy (CB), Brendan Otteman, Shrikant Anant (CB).

    PO.TB06.01 - Chemokines in the Tumor Microenvironment
    2687 - Secretory autophagy offers a novel therapeutic target for head and neck squamous cell carcinoma

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Brendan M. Ottemann, Lauryn Werner, Sufi Thomas (CB)

    PO.TB06.06 - Microbiome
    2911 - Intersection of aging, the microbiome and inflammation in a mouse model of bladder cancer

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Benjamin L. Woolbright (D3ET), Erika Abbott, Ganeshkumar Rajendran, Cuncong Zhong, Hao Xuan, Shahid Umar (CPC),  John Arthur Taylor III (D3ET).

    PO.TB06.07 - Tumor/Stromal Interactions
    3168 - Pancreatic cancer lipid theft is mediated by MAP Kinase signaling in adipocytes

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Joseph Ambrose, Austin E. Eades, McKinnon Walsh, Michael N. VanSaun (CB).

    3170 - Targeting tumor-associated astrocyte dependence in glioblastoma treatment
    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Joseph S. Domino, Anthony Alvarado, Levi Arnold, Sumedha Gunewardena, David Akhavan (D3ET), Sufi M. Thomas (CB)

    PO.TB06.10 - Inflammation and the Tumor Microenvironment
    2824 - SHP2-PDHA metabolic axis is critical for adipocyte function by mitigating ER stress-induced adipocytes dysfunction: Implication for obesity-driven pancreatic ductal adenocarcinoma progression.

    Saturday, April 10, 2021: 8:30 AM - 11:59 PM
    Appolinaire A. Olou, Jarrid Jack, Sharon Manley, Joseph Ambrose, McKinnon Walsh, Austin Eades, Michael N. VanSaun (CB).

    MS.MCB01.01 - Cell Growth Signaling Pathways
    Saturday, April 10, 2021: 4:00 PM - 6:00 PM
    Channel 06

    Chairperson: Sufi M. Thomas (CB).

    April 12
    SS03 - NextGen Stars Spotlight Session: Immunology and Targeted Therapy
    Progesterone-mediated immune evasion in breast cancer

    Monday, April 12, 2021: 2:51 PM - 3:06 PM
    Christy R. Hagan (CB), Lauryn Werner, Emma Helm, Margaret Axelrod, Justin Balko, Zachary Hartman, Kent Hunter, Howard Yang, Prabhakar Chalise (CPC), Mary Markiewicz (CB).

    April 15
    SY02.DISC - Panel— Options and Opportunities for Treating Metastasis

    Wednesday, April 15, 2021: 11:30 AM - 12:00 PM
    Chairperson: Danny R. Welch (CB)
  • Wednesday, December 9

    Special Poster Discussion 2
    8 am
    Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer

    Park KU, Gregory ME, Lustberg MB, Bazan JG, Shen c, Rosenberg SM, Blinder VS, Sharma P, Pusztai L, Partridge AH, Thompson A.

    Poster Session 2
    8 am
    PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial.  
    Paoletti C, Barlow WE, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma PGodwin AK, Thompson AM, Hayes DF, Rae J. 

    Poster Session 6
    8 am
    PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer.

    Yoder R, Kimler BF, Staley JM, Schwensen K, Wang YY, Finke K, O'Dea A, Nye L, Elia M, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Rodriguez R, Shrestha A, Corum L, Marsico M, Godwin AK, Khan Q, Sharma P

    Poster Session 7
    8 am
    PS7-44: Energetics and LifestyLe In InheritEd Syndromes (ELLIE'S Study).  

    Nye LE, Cruz K, Friedman S, Rose D, Befort C, Sullivan DK, Hamilton-Reeves JM, Harlan-Williams LM, Behbod F, Wick J, Irwin M, Klemp J

    Poster Session 11
    8 am
    PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.  

    Aftimos P, Oliveira M, Punie K, Boni V, Hamilton E, Gucalp A, Shah P, Mina L, Sharma P, Bauman L, Campeau E, Attwell S, Snyder M, Norek K, Czibere A, Yu Y, Silverman MH, Lakhotia S, Domchek S, Litton J, Robson M. 

    Poster Session 13
    8 am
    PS13-16: Pharmacokinetic Evaluation of an Oral Paclitaxel DHP107 (Liporaxel®) in Patients with Recurrent or Metastatic Breast Cancer (MBC): Phase II study (OPERA, NCT03326102).

    Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Vidula N, Ji Y, Weng D, Lim H-S, Yoon KE, Cho HJ. 

    Thursday, December 10
    10 am
    GS3-05.  Classification of triple negative breast cancer (TNBC) by DNA Damage Immune Response (DDIR) signature and Homologous Recombination Deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial.
    Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes D, Sharma P

    10:15 am
    GS3-06.  Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

    Hurvitz SA, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamiltion E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortés J, Tsai M, Vahdat L, Diéras V, Carey L, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Bardia A. 

    Panel Discussion
    11:35 am - 12 pm    
    De-escalation trials: What makes sense, what is useless and what's crazy
    Moderator: Eric Winer 
    Panelists:Lisa Carey, Liz Garrett-Mayer, Tari A. King, Priyanka Sharma, Sara M. Tolaney, Julia R. White

    Spotlight Poster Discussion Session 5
    2:15 - 3:30 pm
    Mouse-intraductal (MIND): the first in vivo model to recapitulate the full spectrum of human dcis pathology. Behbod F, Hong Y, Limback D, Elsarraj HS, Harper H, Haines H, Hansford H, Ricci M, Kaufman C, Xu M, Zhang J, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Aripoli A, Huppe A, Winblad O, Balanoff C, Wagner J, Amin AL, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Futreal A, Thompson A, Hwang S, Fan F, On behalf of the Grand Challenge PRECISION consortium. 

    Friday, December 11
    10:15 am
    GS4-07. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore.

    van der Noordaa MEM, Yau C, Shad S, Osdoit M, Steenbruggen TG, de Croze D, Hamy A-S, Lae M, Reyal F, Del Monte-Millán M, Martin M, Lopez Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. 

    Spotlight Poster Session 13
    1 pm – 2:15 pm
    Site of recurrence after neoadjuvant therapy: a multi-center pooled analysis.

    Shad S, van der Noordaa M, Osdoit M, de Croze D, Hamy A-S, Lae M, Reyal F, Martin M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen TG, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, Van't Veer L, Symmans F, Esserman L, Yau C. 

    Spotlight Poster Session 11
    2:15 pm – 3:30 pm
    Randomized trial of 12 months of omega-3 fatty acids vs placebo during a weight loss intervention in post-menopausal women at increased risk for breast cancer.

    Fabian CJ, Befort CA, Sullivan DK, Carlson SE, Nydegger JL, Kreutzjans AL, Powers KR, Phillips TA, Metheny T, Zalles CM, Giles ED, Hursting SD, Kimler BF

    Spotlight Poster Session 12
    3:30 pm - 4:30 pm
    Chronic Health Conditions and Quality of Life in Breast Cancer Survivorship

    Jennifer Klemp, PhD, MPH, MA, Chair,

  • 75: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

    Program: Oral Presentation
    Saturday, December 5, 2020: 7:30 AM

    Ryotaro Nakamura, M.D., Wael Saber, MD, MS, Michael J Martens, PhD, Alyssa Ramirez, Bart L. Scott, MD, Betul Oran, MD, MS, Eric Leifer, Ph.D., Roni Tamari, MD, Asmita Mishra, MD, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Peter Westervelt, MD, PhD, Sumithra Vasu, MD, MBBS, Mrinal M. Patnaik, MD, MBBS, Rammurti Kamble, MD, Stephen J. Forman, MD, Mikkael A. Sekeres, Frederick R. Appelbaum, MD, Adam M. Mendizabal, MS, Brent Logan, PhD, Mary M. Horowitz, MD, MS and Corey Cutler, MD, MPH, FRCPC

    24: A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results  
    Program: Oral Presentation
    Saturday, December 5, 2020: 7:30 AM

    Keith W. Pratz, MD, Mohamad Cherry, MD, MS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD, PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD, PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS and Ramon V. Tiu, MD

    135: High Doses of Targeted Radiation with Anti-CD45 Iodine Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Program: Oral Presentation
    Saturday, December 5, 2020: 9:30 AM

    Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD, MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD, PhD, Mitchell Sabloff, MSc, MD, FRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD PhD

    111: Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Saturday, December 5, 2020: 9:30 AM

    Hartmut Döhner, Andrew H Wei, MBBS, PhD, Pau Montesinos, MD, PhD, Hervé Dombret, MD, Farhad Ravandi, MBBS, Hamid Sayar, MD, MSc, Kimmo Porkka, Irwindeep Sandhu, MD, Francesco Passamonti, Fabrizio Pane, MD, Tadeusz Robak, MD PhD, José F. Falantes, Andre C. Schuh, Gert Ossenkoppele, MD, PhD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Gail J. Roboz, MD

    214: Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Saturday, December 5, 2020: 12:15 PM

    Gail J. Roboz, MD, Hartmut Döhner, Christopher Pocock, MBBS, Hervé Dombret, MD, Farhad Ravandi, MBBS, Jun Ho Jang, MD, PhD, Dominik Selleslag, MD, Jiří Mayer, Uwe M. Martens, MD, Jane L. Liesveld, MD, Teresa Bernal del Castillo, MD, PhD, Ming-Chung Wang, MD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, Julia Braverman, PhD, Salem Abi Nehme, PhD, C.L. Beach, PharmD and Andrew H Wei, MBBS, PhD

    301: Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era
    Program: Oral Presentation
    Saturday, December 5, 2020: 3:15 PM

    Dawn Maze, MD, FRCPC, MSc, Murat O. Arcasoy, MD, Ryan Henrie, MD, BSc, Sonia Cerquozzi, MD, Rammurti Kamble, MD, Samer Al Hadidi, MD, MSc, FACP, Abdulraheem Yacoub, MD, Mahmoud Elsawy, MB, Shireen Sirhan, MD, Anurag K. Singh, MD, Elliot Smith, BSc, Curtis Marcoux, MD MSc, Dietrich Werner, MD, FACP, FRCP, Wenda Greer, PhD, Auro Viswabandya, MD, Andrew Daly, MD, Hassan Sibai, MBBS, Caroline J McNamara, MBBS, Wei Xu, PhD, Katherine Lajkosz, Lynda Foltz, MD, FRCPC and Vikas Gupta, MD, FRCP, FRCPath

    1596: Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample
    Program: Poster Presentation
    Saturday, December 5, 2020

    Ghulam Rehman Mohyuddin, MD, Kellen Gil, Brian McClune, Nausheen Ahmed, Al-Ola Abdallah, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Leyla Shune, MD and Saqib Abbasi

    1582: Patterns and Growth of a Dedicated Pediatric Coagulation Consult Service in a Freestanding Children’s Hospital
    Program: Poster Presentation
    Saturday, December 5, 2020

    Shannon L Carpenter, MD, Eryn Bilynsky, BSN, RN, CCRC, Dena Wideman, MSN, ANP, Kristina D'Agostino, MSN, APRN, Lauren E Amos, MD, Mukta Sharma, MD, MPH and Michael Silvey, DO

    1091: Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients
    Program: Poster Presentation
    Saturday, December 5, 2020

    Sarah Mc Dermott, DO, Midhat S. Farooqi, MD, PhD, Azhar Saeed, MD, Byunggil Yoo, MS, Emily Farrow, PhD, CGC, Neil Miller, Patrick A. Brown, MD and Erin Guest, MD

    934: Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study
    Program: Poster Presentation
    Saturday, December 5, 2020

    Hillard Lazarus, Carolina Escobar, MD, Leland Metheny III, MD, Joseph P. McGuirk, DO, Tsila Zuckerman, MD, Mark Litzow, MD, Scott D. Rowley, MD, Racheli Ofir, PhD, Liran Shani, MD and Jacob M. Rowe, MB, BS

    1123: Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
    Program: Poster Presentation
    Saturday, December 5, 2020

    Morton Coleman, MD, FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD, PhD and Jeff P Sharman, MD

    1149: Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara
    Program: Poster Presentation
    Saturday, December 5, 2020

    Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie José Kersten, MD, PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD, PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD and Catherine Thieblemont, MD, PhD

    1154: Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2  
    Program: Poster Presentation
    Saturday, December 5, 2020

    Pierluigi Porcu, MD, Bradley Haverkos, MD, MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD, PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD, PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD, PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD and Douglas V. Faller, MD, PhD

    990: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients  
    Program: Poster Presentation
    Saturday, December 5, 2020

    Dries Deeren, MD, PhD, Johan A. Maertens, MD, PhD, Tara Lin, MD, Yves Beguin, MD, PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD5, Eytan Breman, Marie-Sophie Dheur, PhD, PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD and Frédéric F. Lehmann, MD

    036: CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Poster Presentation
    Saturday, December 5, 2020

    Andrew Wei, MBBS, PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD, PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Farhad Ravandi, MBBS

    1398: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
    Program: Poster Presentation
    Saturday, December 5, 2020

    Omar Nadeem, MD, Clifton C Mo, MD, Jacob P. Laubach, MD, Giada Bianchi, MD, Robert Redd, Peter Barth, Trevor J. Bayliss, MD, Vaishali Sanchorawala, MD, Leyla Shune, MD, Alexandra Distaso, Virginia Dalton, MS, APRN, Adam S Sperling, MD, PhD, Laura Amweg, Mary McKenney, NP, Kathleen Colson, BS, BSN, RN, Ella L Millard, Isabella Hou, Alexandra Savell, BS, Kelly Masone, BA, Nikhil C. Munshi, MD, Irene M. Ghobrial, MD, Kenneth Anderson, MD and Paul G. Richardson, MD

    1025: V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
    Program: Poster Presentation
    Saturday, December 5, 2020

    Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD, PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung and Vinod A. Pullarkat, MD

    354: Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants.
    Program: Oral Presentation
    Sunday, December 6, 2020: 9:45 AM

    Everett H Meyer, MD, PhD, Rasmus Hoeg, MD, Anna Moroz, MD, PhD, Bryan Xei, BS, Hsin-Hsu Wu, MD, Rahul Pawar, Kartoosh Heydari, MD, David B. Miklos, MD, PhD, Parveen Shiraz, MD, Lori S. Muffly, MD, MS, Sally Arai, MD, MS, Laura J. Johnston, MD, Robert Lowsky, MD, FRCP, Andrew R. Rezvani, MD, Judith A Shizuru, MD, PhD, Wen-Kai Weng, MD, PhD, Nathaniel Fernhoff, PhD, Gerhard Bauer, Arpita Gandhi, MD, MS, Amy Putnam, J. Scott Scott McClellan, MD, PhD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Joseph P. McGuirk, DO, Mehrdad Abedi, MD and Robert S. Negrin, MD

    388: Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
    Program: Oral Presentation
    Sunday, December 6, 2020: 12:00 PM

    Sara Zarnegar-Lumley, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Zhuoxin Sun, PhD, Rhonda E. Ries, MA, Yi-Cheng Wang, MS, Amanda R. Leonti, MS, Matthew A. Kutny, MD, Derek Stirewalt, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Era L Pogosova-Agadjanyan, BS, Kristen Marie O'Dwyer, MD, Harry P. Erba, MD, PhD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD, Mark Litzow, MD, Ehab L. Atallah, MD, Selina M. Luger, MD, FRCPC, Ross L. Levine, MD, Todd M. Cooper, DO, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Soheil Meshinchi, MD, PhD and Katherine Tarlock, MD

    393: The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia
    Program: Oral Presentation
    Sunday, December 6, 2020: 1:15 PM

    Jenny L. Smith, MSc, MEd, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD, PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD, PhD, Alan S. Gamis, MD, MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD, PhD and Soheil Meshinchi, MD, PhD

    479: Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
    Program: Oral Presentation
    Sunday, December 6, 2020: 2:00 PM

    John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, Md, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Alessandro M. Vannucchi, MD and Abdulraheem Yacoub, MD

    482: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients.  
    Program: Oral Presentation
    Sunday, December 6, 2020: 2:45 PM

    Marina Kremyanskaya, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel K Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD, Srdan Verstovsek, MD, PhD and Ronald Hoffman, MD

    468: Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
    Program: Oral Presentation
    Sunday, December 6, 2020: 3:00 PM

    Liora M. Schultz, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Jenna Rossoff, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD and Theodore W. Laetsch, MD

    2039: Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era
    Program: Poster Presentation
    Sunday, December 6, 2020

    Aung M Tun, MD, Raphael Mwangi, Brian K. Link, MD, Andrew L. Feldman, MD, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Anne J. Novak, PhD, Jose C Villasboas, MD, Umar Farooq, MD, Sergei Syrbu, MD, PhD, James R. Cerhan, MD, PhD and Thomas M. Habermann, MD

    1936: Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
    Program: Poster Presentation
    Sunday, December 6, 2020

    Jenna Rossoff, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD and Liora M. Schultz, MD

    2557: A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma.  
    Program: Poster Presentation
    Sunday, December 6, 2020

    Ghulam Rehman Mohyuddin, Jill Hampton, Muhammad Aziz, Sadik Khuder, Ph.D, Saad Ullah Malik, MD, Brian McClune and Al-Ola Abdallah, MD

    3260: First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated Γδ T Cells Following Haploidentical Bone Marrow 
    Program: Poster Presentation
    Sunday, December 6, 2020

    Lawrence S. Lamb Jr., PhD, Melissa Jo Beelen, Samantha Langford Youngblood, BS, Rupal Soder, PhD, Sunil Abhyankar, MD and Joseph P. McGuirk, DO

    2285: Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data  
    Program: Poster Presentation
    Sunday, December 6, 2020

    Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD, PhD, Erica Kim and Brian G.M. Durie, MD

    2314: Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
    Program: Poster Presentation
    Sunday, December 6, 2020

    David S. Siegel, MD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD, PhD, FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, FRCPC, Christopher S. Seet, MD, PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD, PhD and Nizar Bahlis, MD

    1946: Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
    Program: Poster Presentation
    Sunday, December 6, 2020

    Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD

    1917: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial
    Program: Poster Presentation
    Sunday, December 6, 2020

    Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD, PhD, Hamid Sayar, MD, MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD8, William Tse, MD, FACP, Sang Kyun Sohn, MD, PhD, Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Hervé Dombret, MD

    1853: Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies
    Program: Poster Presentation
    Sunday, December 6, 2020

    Nan of Wang, PhD, Corinne Marie Lavasseur, BA, Hongxia Yan, MS, Scott Younger, PhD, Bertil Glader, MD, PhD, Kathleen M. Sakamoto, MD, PhD, Lionel Blanc, PhD and Anupama Narla, MD

    621: CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Monday, December 7, 2020: 9:15 AM

    Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP and Thorsten Braun, MD, PhD

    635: Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
    Program: Oral Presentation
    Monday, December 7, 2020: 12:15 PM

    Jeffrey E. Lancet, MD, Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Donna E. Hogge, Scott R. Solomon, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD, PhD, Daniel H. Ryan, Stefan Faderl, Yu-Lin Chang and Jorge E. Cortes, MD


    636: Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
    Program: Oral Presentation
    Monday, December 7, 2020: 12:30 PM

    Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, M.D., Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, M.D., Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Alice S. Mims, MD

    692: CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial 
    Program: Oral Presentation
    Monday, December 7, 2020: 2:30 PM

    Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD and Gert Ossenkoppele, MD, PhD

    747: Economic and Clinical Burden of Virus Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation 
    Session Name: Health Services Research—Malignant Conditions (Lymphoid Disease) I

    Program: Oral Presentation
    Monday, December 7, 2020: 2:45 PM

    Presenter: Joseph P. McGuirk, DO, The University of Kansas Cancer Center 

    3267: A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC Derived TCR Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell
    Program: Poster Presentation
    Monday, December 7, 2020

    Jae H. Park, MD, Nitin Jain, MD, Andy Chen, MD, PhD, Joseph P. McGuirk, DO, Monica Diaz, Bahram Valamehr, PhD, Yu-Waye Chu, MD and Januario E. Castro, MD

    2887: CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells
    Program: Poster Presentation
    Monday, December 7, 2020

    Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta and Daniel Lopes de Menezes, PhD

    3346: Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML
    Program: Poster Presentation
    Monday, December 7, 2020

    Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD, PhD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD


  • 4703 / 6 - Role of REST in the regulation of MMP24 and estrogen sensitivity in breast cancer

    Aditya M. VargheeseAshley CloudSumedha GunewardenaRaeann ShimakEaswari KumaraswamyRoy A. JensenVargheese M. Chennathukuzhi.

    6405 / 29 - Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting Notch signaling

    Scott James WeirPrasad DandawatePrabhu RamamoorthyParthasarathy RanjarajanRobyn WoodAmanda BrinkerBenjamin Woolbright, Mehmet TanolTammy HamWilliam McCullochMichael DaltonMichael J. BaltezorRoy A. JensenJohn A. Taylor IIIShrikant Anant.

    5150 / 5 - MIF-2 in bladder cancer: potential therapeutic target

    Ganeshkumar RajendranBenjamin L. WoolbrightErika AbbottAustin MartinKatie DennisJohn Arthur Taylor III.

    1120 / 2 - Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer

    Carol J. FabianSeema A. KhanJudy E. GarberWilliam C. DooleyLisa D. YeeCarola M. ZallesTrina MethenyTeresa A. PhillipsJinxiang HuBrian K. PetroffStephen D. HurstingBruce F. Kimler.

    1379 / 15 - Entinostat induces PARPi sensitivity across multiple ovarian cancer models

    Vijayalaxmi G. GuptaShariska Petersen, Jeff HirstKatherine RobyHarsh Pathak, Meghan KuschAndrew WilsonAndrew GodwinDineo Khabele.

    6176 / 16 - Preclinical analysis: BCN057 induces apoptosis in Kras mutant tumors

    Andrew J. NorrisPayel Bhanja, Felipe Rodriguez TiradoAndrew HooverElizabeth M. SingerWilliam McBrideSubhrajit Saha.

    4140 / 17 - Dissecting the structural basis for rational inhibitor design: Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1

    Lan LanMinli XingMaithri KashipathyJustin Douglas, Philip GaoKevin BattaileRobert HanzlikScott LovellLiang Xu.

    2662 / 10 - Mitochondrial genetics appear to alter immune cell development/trafficking

    Thomas C. BeadnellAmanda E. BrinkerCori FainCarolyn J. VivianDanny R. Welch.

    2026 / 4 - Outcomes in elderly patients with non-small-cell lung cancer receiving immune checkpoint inhibitor therapy: A real world experience

    Jacob RippGhulam R. MohyuddinMohammed Al-JumayliChao Huang.

    5417 / 19 - Genomic analysis of infant KMT2A-r acute lymphoblastic leukemia reveals weak association with underlying germline cancer predisposition

    Azhar Saeed, Midhat FarooqiByunggil YooRumen KostadinovEmily FarrowNeil MillerPatrick BrownErin Guest.

    1205 / 13 - Leveraging genome-wide methylation data to understand lung cancer risk in heavy smokers

    Laurie GrieshoberJincheng ShenStefan GrawMatt J. BarnettMark D. ThornquistGary E. GoodmanChu ChenDevin C. KoestlerCarmen J. MarsitJennifer A. Doherty.

    6474 / 8 - FAT1 and CASP8 co-mutations are associated with poor prognosis in HPV negative head and neck squamous cell carcinoma

    Emrullah YilmazDavid LeeAndrew CowanGregory GanMichelle OzbunYan Guo.

    784 / 21 - Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

    Alexander E. PerlJorge E. CortesSiddhartha Ganguly, Samer K. KhaledAlwin KrämerGiovanni MartinelliNigel H. RussellKen C. N. ChangKazunobu KatoYuhu YanLi-An XuSergey KorkhovTobias GünnelHiroyuki SumiArnaud LesegretainFlora BerishaDerek MiresAziz BenzohraTakeshi IsoyamaCedric Dos SantosMark J. Levis.

    CT162 - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

    Ulrich JaegerNina WorelJoseph P. McGuirk, Peter A. RiedellIsabelle FleuryPeter BorchmannSimon NewsomeAhmed M. AbdelhadyAlessandra ForcinaLida Bubuteishvili PacaudEdmund K. Waller.

    LB-258 / 2 - Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

    Barbara BurtnessDanny RischinRichard GreilDenis SoulièresMakoto TaharaGilberto De CastroAmanda PsyrriNeus BastéPrakash NeupaneÅse BratlandThorsten FuerederBrett G. M. HughesRicard MesiaNuttapong NgamphaiboonTamara RordorfWan Zamaniah Wan IshakJoy GeRamona SwabyBurak GumuscuKevin Harrington.

    1921 / 5 - TheDDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial

    Vivek M. ShastriLata ChauhanTodd A. AlonzoYi-Cheng WangRichard AplencBetsy A. HirschAlan S. Gamis, Soheil MeshinchiJatinder K. Lamba.

    3417 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort

    Young Kwang ChaeMegan OthusSandip Pravin PatelMark ZalupskiAnup KasiMaged KhalilAparna KalyanBlase PoliteSarah FentonSewan GurungChristine M. McLeodFrancis GilesHelen X. ChenElad SharonEdward MayersonMelissa PletsChristopher W. RyanCharles D. BlankeRazelle Kurzrock.

State of the Cancer Center Presentation

"State of the Cancer Center" presentation by Dr. Roy Jensen, director of The University of Kansas Cancer Center from KU Cancer Center's Cancer Research Week 2020 event.

Highlights

Hear from our faculty as they discuss major findings presented at ASCO 2020. 

 

ASCO Quality Care Symposium

Dr. Lauren Nye’s presentation from the 2020 ASCO Quality Care Symposium

Related links